TICKER INTELLIGENCE
NYSE/NASDAQ: ABBV
5
Active Bills
0
Gov't Contracts
50
Congressional Trades
AbbVie is a publicly traded company in the Healthcare sector. Operating in the heavily regulated healthcare industry, this company is significantly impacted by Medicare/Medicaid policy changes, FDA regulatory decisions, and pharmaceutical pricing legislation. HillSignal is tracking 5 active Congressional signals mentioning AbbVie, including 5 bills. The current legislative sentiment leans bearish, with regulatory or policy headwinds potentially affecting performance.
⚠ ⚠️ PRESIDENTIAL ACTION: Presidential Memorandum signed 7/30/2026: "Presidential Determination Pursuant to Section 101 of the Defense Production Act of 1950, as Amended". This DPA action will boost investment and production in domestic critical mineral recycling and processing, likely increasing stock valuations for pure-play recovery companies and defense contractors reliant on secure rare-earth magnet supplies, while potentially raising costs for import-dependent manufacturers.
⚠ Rep. Gottheimer bought $250K-$500K and $500K-$1M in MSFT on May 19, 2026 — 14 days before S4656 (DoD AI bill) was introduced, and 15 days before an Executive Order on AI innovation. Both events directly benefit Microsoft's AI and cybersecurity business.
⚠ System: No valid trades to analyze
⚠ System: No overlapping signals found
⚠ Rep. Julie Johnson bought $1,001 - $15,000 in RSG on 2025-12-18, 8 days before S216 ("Save Our Seas 2.0 Amendments Act") was enacted, which could create new revenue streams for waste management.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Rep. Julie Johnson sold $1,001 - $15,000 in ADBE on November 3, 2025 — 2 days before the AI-Related Job Impacts Clarity Act (S3108) was introduced, a bill potentially increasing compliance burdens for tech companies.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Representative Johnson sold $1,001 - $15,000 in APD on 2025-08-14, 20 days before the 'Stop Chinese Fentanyl Act of 2025' (HR747) was introduced. This bill expands sanctions on Chinese entities involved in opioid and precursor production.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Rep. Greene bought $1,001 - $15,000 in UNH on 2025-08-04, 58 days before Optum Public Sector Solutions, a UnitedHealth Group subsidiary, secured a $1.1 billion contract from the Department of Veterans Affairs.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Rep. Gottheimer bought $1,001 - $15,000 in MSFT on 2025-05-21 — 1 day before the "Access Technology Affordability Act of 2025" (S1918) was introduced, which could offer tax credits for technology purchases.
⚠ System: No suspicious timing patterns detected
⚠ Rob Bresnahan bought $1,001 - $15,000 in NVDA on May 12, 2025, May 13, 2025, and May 16, 2025 — 6 to 10 days before the Access Technology Affordability Act of 2025 (S1918) was introduced, a bill that could benefit the company.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Dwight Evans sold $1,001 - $15,000 in ABBV on 2025-04-03, 26 days before the "Medicare for All Act" (HR3069) was introduced, a bill that could impact pharmaceutical companies.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Representative Shreve bought $15,001 - $50,000 in AMGN on February 24, 2025 — 8 days before the EPIC Act of 2025 (S832) was introduced, which proposes to extend market exclusivity for small-molecule drugs.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Rep. Moskowitz bought $1K-$15K in AbbVie (ABBV) on Jan 15, 2025 — 26 days before S.494 (National Plan for Epilepsy Act) was introduced, a bill that could boost epilepsy-related drug demand.
⚠ System: No suspicious timing patterns detected
⚠ Rep. Foxx bought $1K-$15K in JNJ on Dec 6, 2024 — 62 days before HR1062 (Growing and Preserving Innovation in America Act of 2025) was introduced, a bill that would permanently lock in higher tax deductions for US multinationals, directly benefiting Johnson & Johnson's foreign IP income.
⚠ System: No suspicious timing patterns detected
⚠ Rep. Greene bought $1K-$15K in OXY on Nov 20, 2024 — 57 days before the Offshore Energy Security Act (S.109) was introduced, a bill that mandates 20 Gulf of Mexico lease sales over 10 years, directly benefiting oil drillers like Occidental.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
HR8205 reauthorizes ALS research programs through FY2031 but authorizes zero appropriated dollars. The bill is early-stage (referred to committee, no floor vote). Pure-play ALS firms like Cytokinetics are structurally most exposed, but the lack of appropriation and early legislative stage mean no near-term market impact.
HR8083 is an early-stage bill (referred to four committees) that would incentivize OTC switches for routine oral contraceptives via priority review and fee waivers for drugmakers. No explicit funding is authorized — only a GAO study on federal contraceptive funding is directed. At this procedural stage, the bill has zero binding market impact. Pfizer ($PFE at $26.69, down -4.95% over 30 days) and Bristol-Myers Squibb ($BMY at $59.64, down -1.67% over 30 days) have no current revenue exposure to this pathway.
The Protecting Americans from Unsafe Drugs Act of 2026 (HR7980) would expand FDA mandatory recall authority from controlled substances to all drugs, increasing structural operational risk and compliance costs for major pharmaceutical manufacturers. The bill is at an early legislative stage with a single Democratic sponsor, giving it low near-term passage probability. Market data shows the sector is already under pressure in April 2026 with JNJ, PFE, MRK, and AZN all down significantly over 30 days, but this bill is not yet being priced in as a material risk.
→ Manufacturers face increased compliance costs for recall infrastructure and higher potential liability from mandatory recalls.
HR7837, the Most Favored Patient Act of 2026, is a bearish catalyst for major pharmaceutical companies with high Medicare exposure. The bill proposes linking US Medicare drug prices to the lowest global price, directly threatening the US pricing premium that supports current industry margins. The bill is in early legislative stages but represents a credible structural threat to pharmaceutical pricing power.
→ Revenues from Medicare Part B and Part D covered drugs would be repriced to the lowest global price; for blockbuster drugs with a US premium of 2-4x over international reference prices, per-unit revenue declines of 50-75% are implied for the Medicare population.
The 'Protect Infant Formula from Contamination Act' (S.272) passed the Senate on 2026-04-28 and now awaits action in the House. The bill imposes stricter reporting and testing mandates on infant formula manufacturers. AbbVie ($ABBV), as the successor to Abbott Laboratories' nutrition division, bears increased compliance costs with no offsetting funding, creating a negative headwind for its nutrition segment. The stock closed at $203.89 on 2026-04-29, up +3.3% from the prior day but down -4.33% over the last 30 days, reflecting broader market pressures.
→ Increased compliance costs for testing, tracking, reporting systems, and potential for accelerated product recalls and disposal expenses. The bill removes current flexibility in reporting timelines and imposes stringent deadlines and FDA oversight.
Daily AI-analyzed alerts for Congressional activity affecting your portfolio.
Get Started →